Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 1, 2025
Purpose: Disclosure of an investor presentation (Exhibit 99.1) intended for meetings with institutional investors and analysts under Regulation FD.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to announce the availability of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are detailed in this filing. The document references an attached presentation (Exhibit 99.1) which may contain updated information, but the text of the 8-K itself does not quantify changes versus prior periods.
Guidance, Outlook, and Risks
- Management Commentary: The Company is furnishing an investor presentation to be used in meetings with analysts and investors.
- Forward-Looking Statements: The filing explicitly states that the information in the presentation may be amended or updated at any time.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Corporate Presentation dated October 2025) for actual financial data, strategic updates, and guidance, as the 8-K text only references this document.
- Verify the presentation on the Company's website at www.aquestive.com under the Events and Presentations page, noting the Company reserves the right to discontinue availability.
- Confirm that the presentation is not legally "filed" for liability purposes under Section 18 of the Exchange Act.